0PT Stock Chart & Stats
€9.09
€0.00(0.00%)
At close: 4:00 PM EST
€9.09
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.20 - €9.76
Previous CloseN/A
Volume0.00
Average Volume (3M)27.00
Market Cap
€442.01M
Enterprise Value€122.67M
Total Cash (Recent Filing)€329.46M
Total Debt (Recent Filing)€7.65M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Aug 10, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.81
Shares Outstanding52,353,237
10 Day Avg. Volume81
30 Day Avg. Volume27
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.83
Price to Sales (P/S)53.08
P/FCF Ratio-3.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.70Price Target Upside105.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.21
Revenue Forecast (FY)€74.99M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetVery low debt-to-equity (c.1%–5%) reduces refinancing and interest-rate risk, preserving financial optionality. For a clinical-stage biotech this supports continued R&D spending and the ability to fund trials or partnerships without immediate debt pressure, a durable strength over months.
Partner Collaborations & Licensing ModelRevenue driven by upfronts, R&D reimbursements, milestones and royalties from partners (not product sales) provides structural funding pathways. This model de-risks program costs, supports pipeline advancement, and can extend the company’s runway when partnerships succeed.
Focused Pipeline On ProteinopathiesConcentrated expertise in immunotherapies targeting misfolded proteins (e.g., alpha-synuclein) aligns with long-term unmet needs in neurodegeneration. Specialized scientific focus and partnered programs create durable competitive differentiation and relevance as aging-related diseases remain structural tailwinds.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow since 2022 creates recurring funding needs. Over a 2–6 month horizon this heightens dilution or financing risk and constrains internal funding of multiple clinical programs absent consistent milestone receipts or partner financing.
Negative TTM Gross Profit And Deep LossesA negative TTM gross margin and widening net losses indicate core profitability issues, not just timing effects. Persistent losses erode equity, reduce internal reinvestment capacity, and can impair negotiating leverage with partners and investors over the medium term.
Highly Volatile, Episodic RevenueDependence on upfronts, milestones and reimbursements causes lumpy top-line recognition and weak predictability. This episodic revenue profile complicates cash planning and budgeting, increasing the probability of interim financing and making multi-program advancement harder to sustain without partners.
Prothena News
0PT FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was €5.20 and its highest was €9.76 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is €442.01M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Aug 10, 2026 which is in 29 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on May 07, 2026. The company reported €0.525 earnings per share for the quarter, beating the consensus estimate of -€0.305 by €0.83.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.34.
How many shares outstanding does Prothena have?
Prothena has 52,353,237 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of €0.525 in its last earnings report, beating expectations of -€0.305. Following the earnings report the stock price went down -4.032%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in DE:0PT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€18.70 (105.74% Upside)
€18.70 (105.74% Upside)
Insider Transactions
Bought Shares
Worth €2.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.42%
12-Months-Change
Fundamentals
Return on Equity
-49.88%
Trailing 12-Months
Asset Growth
-29.36%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
0PT Company Deck
0PT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.View all DE:0PT earnings summaries0PT Stock 12 Month Forecast
Average Price Target
€18.70
▲(105.74% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
XOMA Royalty Corporation
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―
Options Prices
Currently, No data available
---